Which of the following is NOT a characteristic of Pivotal/IDE trial designs used for FDA approval?

• A. Confirms safety, efficacy, and risks
• B. Statistically driven
• C. Small groups of people
• D. Compares to commonly used treatments in a randomized manner

Answer: (C)

The characteristic that is not associated with Pivotal/Investigational Device Exemption (IDE) trial designs used for FDA approval is the use of small groups of people. Pivotal trials are designed to gather sufficient data to demonstrate the safety and efficacy of a device or treatment. To achieve this, they typically involve larger populations, ensuring that the study outcomes are statistically significant and representative of the broader patient population that the device or treatment is intended for.

Larger sample sizes in these trials allow for better estimation of the product's effects, collecting enough varied data to assess safety, perform subgroup analyses, and understand the risks involved comprehensively. In contrast, smaller groups might not yield enough statistical power or might limit the generalizability of the findings. Thus, opting for a larger and more diverse cohort is essential for making informed regulatory decisions based on the trial results.